addextherapeutics.com (ADXN) - Long-Term Liabilities to Capital

This daily price chart for Addex Therapeutics (ADXN) reflects the asset's dynamics, with a value of 0.01. Addex Therapeutics is developing therapies for epilepsy and Parkinson's disease, utilizing allosteric modulation to reduce toxicity. The business relies on a scalable molecule discovery platform, passing final trial costs onto partners. High scientific authority and global alliances confirm its status as a leader in neurobiology.

This ratio determines the dependence of long-term financing on the company's equity. It measures the risk of mismatch between borrowed funds with a repayment horizon of over one year and the market value of assets. By analyzing the trajectory of the long-term debt-to-equity ratio, an investor assesses the financial stability of the business. For Addex Therapeutics (ADXN), this balance is critical when investing in the development of unique allosteric modulators. Debt control provides the company with pricing power when bringing drugs to market.